A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis

Nature Genetics

Volumn 43, Issue 9, 2011, Pages 908-912

  Matmati, Mourad ^a,b   Jacques, Peggy ^c   Maelfait, Jonathan ^a,b   Verheugen, Eveline ^c   Kool, Mirjam ^a,c   Sze, Mozes ^a,b   Geboes, Lies ^d   Louagie, Els ^c   Guire, Conor Mc ^a,b   Vereecke, Lars ^a,b   Chu, Yuanyuan ^e   Boon, Louis ^f   Staelens, Steven ^b,g   Matthys, Patrick ^d   Lambrecht, Bart N ^c   Schmidt Supprian, Marc ^e   Pasparakis, Manolis ^h   Elewaut, Dirk ^c   Beyaert, Rudi ^a,b   Van Loo, Geert ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^f BIOCEROS   (Netherlands)

^g UNIVERSITY OF ANTWERP   (Belgium)

^h UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 20F3; MONOCLONAL ANTIBODY MP6 XT22; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN A20; REGULATOR PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; PERITONEUM MACROPHAGE; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CYSTEINE ENDOPEPTIDASES; CYTOKINES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MICE; MICE, KNOCKOUT; MYELOID CELLS; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 80052195163     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.874     Document Type: Article

References (31)

1. Coornaert, B., Carpentier, I. & Beyaert, R. A20: central gatekeeper in inflammation and immunity. J. Biol. Chem. 284, 8217-8221 (2009).
2. Wertz, I.E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
3. Boone, D.L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052-1060 (2004). (Pubitemid 41057725)
4. Hitotsumatsu, O. et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28, 381-390 (2008). (Pubitemid 351343859)
5. Düwel, M. et al. A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J. Immunol. 182, 7718-7728 (2009).
6. Lee, E.G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354 (2000).
7. Vereecke, L., Beyaert, R. & van Loo, G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30, 383-391 (2009).
8. Vereecke, L. et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207, 1513-1523 (2010).
9. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R. & Forster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999). (Pubitemid 29523965)
10. Turer, E.E. et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J. Exp. Med. 205, 451-464 (2008). (Pubitemid 351281609)
11. Taylor, P.C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578-582 (2009).
12. Rothe, J. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993). (Pubitemid 23261759)
13. Huang, Q.Q. & Pope, R.M. The role of Toll-like receptors in rheumatoid arthritis. Curr. Rheumatol. Rep. 11, 357-364 (2009).
14. Hennessy, E.J., Parker, A.E. & O'Neill, L.A. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307 (2010).
15. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 9, 143-150 (1998). (Pubitemid 28361303)
16. Aoki, S. et al. Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Ann. Rheum. Dis. 55, 363-369 (1996). (Pubitemid 26189180)
17. Yoshino, S., Sasatomi, E., Mori, Y. & Sagai, M. Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J. Immunol. 163, 3417-3422 (1999). (Pubitemid 29431845)
18. Nieuwenhuis, E.E. et al. Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli. Arthritis Rheum. 43, 2583-2589 (2000).
19. Vaahtovuo, J., Munukka, E., Korkeamaki, M., Luukkainen, R. & Toivanen, P. Fecal microbiota in early rheumatoid arthritis. J. Rheumatol. 35, 1500-1505 (2008).
20. McInnes, I.B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442 (2007). (Pubitemid 46834849)
21. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006). (Pubitemid 44833343)
22. Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992).
23. Wada, T., Nakashima, T., Hiroshi, N. & Penninger, J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17-25 (2006). (Pubitemid 43089652)
24. Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97, 1566-1571 (2000). (Pubitemid 30118482)
25. Criscione, L.G. & St. Clair, E.W. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr. Opin. Rheumatol. 14, 204-211 (2002). (Pubitemid 34439081)
26. Plenge, R.M. et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 39, 1477-1482 (2007). (Pubitemid 350191346)
27. Thomson, W. et al. Rheumatoid arthritis association at 6q23. Nat. Genet. 39, 1431-1433 (2007). (Pubitemid 350191348)
28. Rodríguez, C.I. et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25, 139-140 (2000). (Pubitemid 30394979)
29. Onizawa, M. et al. Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G850-G859 (2009).
30. Starnes, H.F. et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol. 145, 4185-4191 (1990).
31. Geboes, L. et al. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-γ receptor by triggering tumor necrosis factor α-driven osteoclastogenesis. Arthritis Rheum. 56, 2595-2607 (2007). (Pubitemid 47237278)